Castration Resistant Prostate Cancer (CRPC): State of the Art, Perspectives and New Challenges

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 16, 12 Issues, 2016

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Castration Resistant Prostate Cancer (CRPC): State of the Art, Perspectives and New Challenges

Anti-Cancer Agents in Medicinal Chemistry, 13(6): 872-886.

Author(s): Francesco Massari, Francesca Maines, Alessandra Modena, Matteo Brunelli, Emilio Bria, Walter Artibani, Guido Martignoni and Giampaolo Tortora.

Affiliation: Medical Oncology, ‘G.B. Rossi’ Academic Hospital, University of Verona, Piazzale L.A. Scuro 10, 37124, Verona, Italy.


The rapid approval of several novel agents has given prostate cancer patients and their treating physicians many new and effective therapeutic options. Four new medical therapies were recently approved on the basis of prolonged overall survival in castrationresistant prostate cancer (CRPC) patients: sipuleucel-T, cabazitaxel, abiraterone acetate and MDV3100. Additionally, there are several other promising prostate cancer agents in late-stage development, including PROSTVAC-VF, orteronel and radium-223 chloride, each with a novel mechanism of action. The treatment paradigm for these patients is rapidly evolving, with future study needed to define the optimal sequencing and potential combinations of these new agents. In this review, we discuss the recent progress in understanding the biology of this disease and examining the development of a variety of new agents with promising activity and a favorable toxicity profile, that have been investigated in the setting of hormonal, cytotoxic, immune and targeted therapy. In this new therapeutic setting of CRPC, clinicians will have an opportunity to balance benefits and harms of these new agents in an individual context.


Agents targeting bone, castration resistant prostate cancer, chemotherapy, hormone therapy, immunotherapy.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 13
Issue Number: 6
First Page: 872
Last Page: 886
Page Count: 15
DOI: 10.2174/18715206113139990077
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science